Table 1 Clinical and histological features of the primary tumour and metastatic disease in the ESME cohort and main study population.
Whole ESME population | Main study population | Whole ESME population | Main study population | ||
|---|---|---|---|---|---|
(n = 16,703) | (n = 1677) | (n = 16,703) | (n = 1677) | ||
At initial diagnosis | Chemotherapy and/or targeted therapy | ||||
Age: median (range) | 54 (19: 98) | 51 (23: 91) | No | 3723 (30.7%) | 411 (28.3%) |
<50 years | 6258 (37.6%) | 730 (43.6%) | Yes | 8410 (69.3%) | 1042 (71.7%) |
50–70 years | 7883 (47.3%) | 808 (48.2%) | Missing | 18 | 2 |
>70 years | 2517 (15.1%) | 138 (8.2%) | Endocrine therapy | ||
Missing | 45 | 1 | No | 4207 (34.7%) | 425 (29.2%) |
Sex | Yes | 7930 (65.3%) | 1029 (70.8%) | ||
Male | 149 (0.9%) | 18 (1.1%) | Missing | 14 | 1 |
Female | 16554 (99.1%) | 1659 (98.9%) | At MBC diagnosis | ||
Menopausal status | Age: median (range) | 61 (19: 99) | 60 (24: 93) | ||
Yes | 11,670 (69.9%) | 1132 (67.5%) | Time to MBC | ||
No | 4884 (29.2%) | 527 (31.4%) | <6 months | 4763 (28.6%) | 226 (13.5%) |
Not applicable | 149 (0.9%) | 18 (1.1%) | 6–24 months | 2186 (13.1%) | 182 (10.9%) |
Histological type | >24 months | 9709 (58.3%) | 1268 (75.7%) | ||
Invasive carcinoma NST | 11,902 (79.8%) | 1306 (83.0%) | Missing | 45 | 1 |
Invasive lobular | 2088 (14.0%) | 185 (11.8%) | Number of metastatic sites | ||
Other | 917 (6.2%) | 83 (5.3%) | 1 site | 9270 (55.5%) | 667 (39.8%) |
Missing | 1796 | 103 | 2 sites | 4017 (24.0%) | 494 (29.5%) |
ER status at diagnosis | ≥3 sites | 3416 (20.5%) | 516 (30.8%) | ||
Positive | 9690 (75.0%) | 1223 (75.5%) | Metastatic site of sampling | ||
Negative | 3171 (24.5%) | 384 (23.7%) | (n = 2933) | (n = 1677) | |
Heterogeneous | 66 (0.5%) | 13 (0.8%) | CNS/CSF | 132 (4.6%) | 42 (2.6%) |
Missing | 3776 | 57 | Bone | 692 (24.2%) | 419 (25.5%) |
PR status at diagnosis | Lung | 258 (9.0%) | 168 (10.2%) | ||
Positive | 7035 (55.8%) | 908 (57.7%) | Lymph node | 306 (10.7%) | 169 (10.3%) |
Negative | 5435 (43.1%) | 652 (41.4%) | Pleural | 283 (9.9%) | 121 (7.4%) |
Heterogeneous | 129 (1.0%) | 13 (0.8%) | Skin | 379 (13.3%) | 203 (12.4%) |
Missing | 4104 | 104 | Liver | 514 (18.0%) | 355 (21.6%) |
HER2 status at diagnosis | Other | 273 (9.5%) | 151 (9.2%) | ||
Positive | 2070 (18.1%) | 190 (14.7%) | Several | 23 (0.8%) | 14 (0.9%) |
Negative | 9187 (80.1%) | 1064 (82.5%) | Missing | 73 | 35 |
Equivocal | 143 (1.2%) | 26 (2.0%) | ER status on metastatic biopsy | ||
Heterogeneous | 63 (0.5%) | 9 (0.7%) | Positive | 1601 (72.2%) | 1163 (71.7%) |
Missing | 5240 | 388 | Negative | 617 (27.8%) | 459 (28.3%) |
Primary tumour subtype | Missing | 715 | 55 | ||
TNBC | 1897 (17.5%) | 218 (18.1%) | PR status on metastatic biopsy | ||
HR+/ HER2− | 6898 (64.1%) | 795 (66.4%) | Positive | 904 (42.1%) | 669 (42.7%) |
HR−/HER2+ | 821 (7.6%) | 72 (6.0%) | Negative | 1241 (57.9%) | 899 (57.3%) |
HR+/ HER2+ | 1148 (10.7%) | 113 (9.4%) | Missing | 788 | 109 |
Missing | 5939 | 479 | HER2 status on metastatic biopsy | ||
De novo MBC | Positive | 342 (16.5%) | 230 (15.3%) | ||
Yes | 4507 (27.1%) | 221 (13.2%) | Negative | 1670 (80.5%) | 1230 (81.7%) |
No | 12151 (72.9%) | 1455 (86.8%) | Equivocal | 63 (3.0%) | 45 (3.0%) |
Missing | 45 | 1 | Missing | 858 | 172 |
Management of primary tumour (n = 12,151) | MBC subtypes | ||||
TNBC | 356 (18.5%) | 272 (19.3%) | |||
Radiotherapy | HR+/HER2− | 1251 (65.0%) | 917 (65.2%) | ||
No | 1712 (14.1%) | 131 (9.0%) | HR−/HER2+ | 150 (7.8%) | 105 (7.5%) |
Yes | 10,426 (85.9%) | 1324 (91.0%) | HR+/HER2+ | 168 (8.7%) | 112 (8.0%) |
Missing | 13 | 0 | Missing | 1008 | 271 |
